Research Article

Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil

Volume: 23 Number: 2 June 27, 2025

Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil

Abstract

Acidic dissociation constant (pKa) is an important physicochemical parameter in absorption, dissociation and elimination mechanisms of drugs in body. Various analytical methods are utilized for the determination of pKa values of pharmaceutical active ingredients, and potentiometry, spectrophotometry and HPLC are the most common methods. Cabergoline is dopaminergic ergoline derivative having a powerful and long-term prolactin reducing effect, which is used for the treatment of Parkinson disease. Tadalafil leads an increasing cGMP level in Corpus cavernous, during secretion of nitric oxide in sexual arousal. In the presented study, detection of pKa values for Cabergoline and Tadalafil by using potentiometry, spectrophotometry and HPLC was investigated. The pKa value for Cabergoline was respectively found to be 6.42, 6.05 and 6.20 by spectrophotometry, potentiometry and HPLC. Spectrophotometric pKa value was significantly different (p>0.05) from others, and potentiometry and spectrophotometry were appropriate for pKa value determination of Cabergoline. The pKa values for Tadalafil by potentiometry and spectrophotometry were found to be 3.52 and 3.44, respectively. But, in HPLC, no differentiation was observed in retention times of Tadalafil by increasing pH value of mobile phase. Developed methods for determination of pKa values for Cabergoline and Tadalafil demonstrated high repeatability values (RSD<%1). In this study, experimental pKa values for Cabergoline and Tadalafil from developed methods were compared with the values calculated by the common softwares and high-level divergences were observed.

Keywords

References

  1. [1] Skoog, D., West, D., Holler, F., & Crouch, S. (1992). Fundamentals of Analytical Chemistry (8th ed.). Brooks/Cole, New York, USA.
  2. [2] Kayaalp, O. (1996). Tıbbi Farmakoloji. Hacettepe-Taş, Türkiye.
  3. [3] Colao, A., Lombardi, G., & Annunziato, L. (2000). Cabergoline. Expert Opinion on Pharmacotherapy, 1(3), 555–574. https://doi.org/10.1517/14656566.1.3.555
  4. [4] Curran, M. P., & Perry, C. M. (2004). Cabergoline: A review of its use in the treatment of Parkinson's disease. Drugs, 64(18), 2125–2141. https://doi.org/10.2165/00003495-200464180-00011
  5. [5] Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I. (2006). Tadalafil pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 61(3), 280–288. https://doi.org/10.1111/j.1365-2125.2005.02553.x
  6. [6] Pianezzola, E., Bellotti, V., La Croix, R., & Strolin Benedetti, M. (1992). Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B: Biomedical Sciences and Applications, 574(1), 170–174. https://doi.org/10.1016/0378-4347(92)80103-7
  7. [7] Igarashi, K., Hotta, K., Kasuya, F., Abe, K., & Sakoda, S. (2003). Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 792(1), 55–61. https://doi.org/10.1016/S1570-0232(03)00277-2
  8. [8] Kimball, B. A., DeLiberto, T. J., & Johnston, J. J. (2001). Determination of cabergoline by electrospray ionization tandem mass spectrometry: Picogram detection via column focusing sample introduction. Analytical Chemistry, 73(20), 4972–4976. https://doi.org/10.1021/ac010468x

Details

Primary Language

English

Subjects

Pharmaceutical Analytical Chemistry

Journal Section

Research Article

Authors

Merve Banu Polat This is me
Türkiye

Publication Date

June 27, 2025

Submission Date

June 11, 2018

Acceptance Date

October 31, 2018

Published in Issue

Year 2019 Volume: 23 Number: 2

APA
Polat, M. B., Doğan, A., & Başcı Akduman, N. E. (2025). Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. Journal of Research in Pharmacy, 23(2), 177-186. https://izlik.org/JA59FW22BH
AMA
1.Polat MB, Doğan A, Başcı Akduman NE. Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. J. Res. Pharm. 2025;23(2):177-186. https://izlik.org/JA59FW22BH
Chicago
Polat, Merve Banu, Ayşegül Doğan, and Nursabah Elif Başcı Akduman. 2025. “Spectrophotometry, Potentiometry and HPLC in Determination of Acidity Constant for Cabergoline and Tadalafil”. Journal of Research in Pharmacy 23 (2): 177-86. https://izlik.org/JA59FW22BH.
EndNote
Polat MB, Doğan A, Başcı Akduman NE (June 1, 2025) Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. Journal of Research in Pharmacy 23 2 177–186.
IEEE
[1]M. B. Polat, A. Doğan, and N. E. Başcı Akduman, “Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil”, J. Res. Pharm., vol. 23, no. 2, pp. 177–186, June 2025, [Online]. Available: https://izlik.org/JA59FW22BH
ISNAD
Polat, Merve Banu - Doğan, Ayşegül - Başcı Akduman, Nursabah Elif. “Spectrophotometry, Potentiometry and HPLC in Determination of Acidity Constant for Cabergoline and Tadalafil”. Journal of Research in Pharmacy 23/2 (June 1, 2025): 177-186. https://izlik.org/JA59FW22BH.
JAMA
1.Polat MB, Doğan A, Başcı Akduman NE. Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. J. Res. Pharm. 2025;23:177–186.
MLA
Polat, Merve Banu, et al. “Spectrophotometry, Potentiometry and HPLC in Determination of Acidity Constant for Cabergoline and Tadalafil”. Journal of Research in Pharmacy, vol. 23, no. 2, June 2025, pp. 177-86, https://izlik.org/JA59FW22BH.
Vancouver
1.Merve Banu Polat, Ayşegül Doğan, Nursabah Elif Başcı Akduman. Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. J. Res. Pharm. [Internet]. 2025 Jun. 1;23(2):177-86. Available from: https://izlik.org/JA59FW22BH